William P’pool Sells 8,987 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) Stock

Prestige Consumer Healthcare Inc. (NYSE:PBH) insider William P’pool sold 8,987 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the transaction, the insider now owns 20,058 shares of the company’s stock, valued at approximately $1,641,747.30. This trade represents a 30.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Prestige Consumer Healthcare Price Performance

Shares of NYSE PBH opened at $82.36 on Friday. The firm has a market capitalization of $4.07 billion, a P/E ratio of 20.04, a P/E/G ratio of 2.32 and a beta of 0.47. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. The stock’s 50-day simple moving average is $73.13 and its two-hundred day simple moving average is $70.18. Prestige Consumer Healthcare Inc. has a twelve month low of $56.61 and a twelve month high of $83.83.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The business had revenue of $283.79 million during the quarter, compared to analyst estimates of $282.09 million. During the same period in the previous year, the business posted $1.07 earnings per share. Prestige Consumer Healthcare’s revenue for the quarter was down .9% on a year-over-year basis. As a group, equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on PBH shares. DA Davidson reaffirmed a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Jefferies Financial Group reaffirmed a “hold” rating and set a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. One investment analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $83.67.

Institutional Trading of Prestige Consumer Healthcare

A number of hedge funds have recently made changes to their positions in PBH. State Board of Administration of Florida Retirement System raised its position in Prestige Consumer Healthcare by 77.4% during the first quarter. State Board of Administration of Florida Retirement System now owns 25,221 shares of the company’s stock valued at $1,830,000 after purchasing an additional 11,000 shares in the last quarter. Lombard Odier Asset Management USA Corp purchased a new position in shares of Prestige Consumer Healthcare during the 2nd quarter valued at about $550,000. CANADA LIFE ASSURANCE Co lifted its position in Prestige Consumer Healthcare by 19.4% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 47,575 shares of the company’s stock worth $3,453,000 after buying an additional 7,715 shares during the last quarter. Sequoia Financial Advisors LLC boosted its stake in Prestige Consumer Healthcare by 12.9% in the third quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company’s stock worth $708,000 after buying an additional 1,120 shares in the last quarter. Finally, Atria Investments Inc purchased a new position in shares of Prestige Consumer Healthcare during the first quarter worth approximately $1,246,000. 99.95% of the stock is owned by institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.